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ABSTRACT
Purpose: We aimed to evaluate the clinical characteristics of microsatellite instability in early 
gastric cancer.
Materials and Methods: The microsatellite instability status of resected early gastric tumors 
was evaluated using two mononucleotide repeat markers (BAT25 and BAT26) and three 
dinucleotide repeat markers (D5S346, D2S123, and D17S250). Tumors with instability in two 
or more markers were defined as microsatellite instability-high (MSI-H) and others were 
classified as microsatellite stable (MSS).
Results: Overall, 1,156 tumors were included in the analysis, with 85 (7.4%) classified as 
MSI-H compared with MSS tumors. For MSI-H tumors, there was a significant correlation 
with the female sex, older age, tumor location in the lower gastric body, intestinal histology, 
lymphovascular invasion (LVI), and submucosal invasion (P<0.05). There was also a trend 
toward an association with lymph node (LN) metastasis (P=0.056). In mucosal gastric cancer, 
there was no significant difference in MSI status in tumors with LN metastasis or tumors 
with LVI. In submucosal gastric cancer, LVI was more frequently observed in MSI-H than in 
MSS tumors (38.9% vs. 25.0%, P=0.027), but there was no difference in the presence of LN 
metastases. The prognosis of MSI-H tumors was similar to that of MSS tumors (log-rank test, 
P=0.797, the hazard ratio for MSI-H was adjusted by age, sex, pT stage, and the number of 
metastatic LNs, 0.932; 95% confidence interval, 0.423–2.054; P=0.861).
Conclusions: MSI status was not useful in predicting prognosis in early gastric cancer. However, 
the frequent presence of LVI in early MSI-H gastric cancer may help guide the appropriate 
treatment for patients, such as endoscopic treatment or limited LN surgical dissection.
Keywords: Microsatellite instability; Gastric cancer; Prognosis; Lymph nodes
INTRODUCTION
Gastric cancer is a major global health burden, accounting for nearly one million new cases 
and 720,000 deaths worldwide in 2012 [1]. Gastric cancer is one of the most common 
cancer types in Korea [2] and with well-established screening practices, the proportion of 
early gastric cancer is high in countries, such as Korea and Japan [3]. While the prognosis 
for early gastric cancer is relatively favorable, 5%–20% of these patients have lymph node 
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(LN) metastases at the time of diagnosis [4] and 5%–10% experience cancer recurrence after 
surgical treatment [5,6]. Variable molecular characteristics are responsible for the diverse 
clinical features and prognosis [7-9] in patients with gastric cancer. Discovering biomarkers 
related to LN metastasis and prognosis are essential for improving patient care [10].
Microsatellite instability (MSI), which is characterized by an inability to repair microsatellite 
regions, is a molecular phenotype arising from defects in DNA mismatch repair (MMR) 
machinery [11,12]. Accordingly, a high level of MSI is associated with an increased mutation 
rate [13]. MSI is related to inherited disorders caused by MMR gene mutations such as in 
Lynch syndrome [14], and the sporadic type of MSI cancer is mainly caused by silencing 
of the mut1 homolog 1 (MLH1) gene, a consequence of CpG island hypermethylation [15]. 
The MSI phenotype is a molecular subtype that is recognized in gastric cancer [13,16]. The 
proportion of MSI-H gastric cancers was reported as approximately 5%–37%, and was related 
to females, older age, intestinal histology, less frequent LN metastasis, and earlier tumor 
stages [17-21]. In addition, recent post-hoc analyses of randomized controlled trials [22,23] 
showed that MSI-H tumors are related to a favorable prognosis and MSI status may be a 
marker for predicting chemotherapy responsiveness for stage II/III gastric cancer. However, 
the clinical implications of MSI status in early gastric cancer have not been thoroughly 
evaluated. We hypothesized that MSI status is a predictor for LN metastasis and prognosis in 
early gastric cancer.
MATERIALS AND METHODS
Data collection
Data were obtained from patients who underwent gastrectomy for gastric cancer with 
curative intent at Severance Hospital, in the Yonsei University Health System, between 
January 2005 and June 2010 [24]. MSI status was reported for 2,549 of these patients. 
Patients with prior gastric surgery or neoadjuvant chemotherapy were excluded (n=32). We 
also excluded cancers that invaded more than the proper muscle layer (n=1,361) but included 
cancers with the invasion of the mucosa or submucosa. Gastric adenocarcinoma was 
histologically confirmed for all included patients. A total of 1,156 patients were included in 
the final analysis. Information was obtained with the appropriate Institutional Review Board 
approval, and data were collected without revealing any personal information.
Clinicopathological variables
We retrospectively recorded clinicopathological features, including age, sex, tumor location, 
tumor size, histological type, Lauren classification, pT stage, number of resected LNs, 
number of metastatic LNs, lymphovascular invasion (LVI), and MSI status. Additional 
immunohistochemistry for detecting LN micrometastases was not routinely performed. 
Patient survival was determined from hospital records, the database of the Korean National 
Statistical Office, and telephone surveys. The patients were evaluated for 5 years after surgery 
to monitor for tumor recurrence. Evaluations included a physical examination, laboratory 
testing, diagnostic imaging, and endoscopy. Patient prognosis was evaluated by disease-free 
survival (DFS) and the median follow-up period was 72 months, with a range of 1–98 months.
MSI status definition
To determine the MSI status, DNA was extracted from the paraffin blocks of each patient's 
tumor specimen for polymerase chain reaction amplification and fragment analysis, as 
428https://jgc-online.org https://doi.org/10.5230/jgc.2019.19.e38
MSI in EGC
described previously [17]. MSI analysis was performed using the Revised Bethesda Guidelines 
for two mononucleotides (BAT 25 and BAT 26) and 3 dinucleotide (D2S123, D5S346, and 
D17S250) microsatellite markers [25]. If the number of unstable markers was 0 or 1, the 
tumor was clinically defined as microsatellite stable (MSS), while a tumor with 2 or more 
unstable markers was defined as microsatellite instability-high (MSI-H).
Tumor staging and histological classification
Tumors were staged according to the 7th edition of the International Union Against Cancer 
classification [26]. Histologically, tumors were classified into two categories, differentiated 
or undifferentiated types. Differentiated tumors include papillary, well- or moderately-
differentiated, and tubular adenocarcinomas, while undifferentiated types include 
poorly-differentiated tubular adenocarcinoma, signet ring cell carcinoma, and mucinous 
carcinoma. Another way to classify tumors is by using the Lauren classification system, 
which classifies tumors into 3 categories: intestinal type, diffuse type, and others (including 
mixed types) [27].
Statistical methods
Clinical and pathological data were analyzed with IBM SPSS® software, version 23.0 
for Windows® (SPSS, Chicago, IL, USA). To analyze continuous variables, we used the 
independent t-test. Categorical data were analyzed with Pearson's χ2 test and Fisher's exact 
test. Survival data were analyzed using the Kaplan-Meier method, log-rank test, and Cox's 
proportional hazards model. Univariable and multivariable analyses in the Cox model were 
described with hazard ratios (HRs) and their 95% confidence interval (CI). Variables that 
were statistically significant in univariable analysis were included in multivariable analysis 
without any selection method. Age and sex were used as adjustment variables for adjusted 
HRs. DFS was defined as the date from operation to death or recurrence, whichever occurred 
first. Statistical significance was defined as having a P-value <0.05.
Ethics statement
This study was conducted in accordance with the Ethical Principles for Medical Research 
Involving Human Subjects, as outlined in the Declaration of Helsinki after the approval of the 
Institutional Review Board of Severance Hospital, Yonsei University Health System (IRB No. 
4-2019-0081).
RESULTS
Clinical characteristics
Among 1,156 patients with early gastric cancer, 85 patients (7.4%) had MSI-H gastric cancer. 
The MSI-H type of gastric cancer was related to older age (63.4 vs. 56.7 years, P<0.001), 
female sex (54.1% vs. 32.8%, P<0.001), location in the lower third of the stomach (81.2% 
vs. 59.7%, P<0.001), a histologically differentiated type (71.8% vs. 50.0%, P<0.001), 
and intestinal-type dominance by Lauren classification (63.5% vs. 48.2%, P=0.002) in 
comparison to the MSS type. The depth of invasion for the MSI-H type was deeper than the 
MSS type, with 63.5% of the MSI-H showing submucosal invasion while only 48.3% was seen 
with the MSS type (P=0.007). A trend toward more LN metastases in the MSI-H tumors was 
observed but was not statistically significant (17.6% vs. 10.8%, P=0.056). However, more LVI 
was observed in the MSI-H type compared to the MSS type (25.9% vs. 13.3%, P=0.001). These 
data and further details are summarized in Table 1.
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Patient prognosis by MSI status
As Fig. 1 depicts, the prognosis of MSI-H tumors did not differ from that of MSS tumors in 
patients with early gastric cancer (log-rank, P=0.797; age-, sex-, pT stage-, and the number of 
metastatic LN-adjusted HR was 0.932; 95% CI, 0.423–2.054; P=0.861). MSI status was not a 
significant prognostic factor in univariable or multivariable Cox analyses (HR, 1.107; 95% CI, 
0.511–2.398; P=0.7970 and HR, 0.855; 95% CI, 0.387–1.890; P=0.699, respectively) (Table 2). 
In the subgroup analysis by pT stage (mucosa and submucosa) (Fig. 2A and B), the Lauren 
classification (intestinal and diffuse type) (Fig. 2C and D), and the LN metastasis (without 
and with LN metastasis) (Fig. 2E and F), there were no differences or trends for prognosis by 
MSI status.
LN metastasis and LVI by MSI status
As there was a trend and significant association between LN metastasis, LVI, and MSI 
status, we conducted subgroup analyses. In gastric cancer with mucosal invasion, there 
was no significant difference between LN metastasis and LVI based on MSI status (P=0.755 
and P=0.755, respectively) (Table 3). In submucosal cancer, no significant association was 
observed between LN metastasis and MSI status concerning overall submucosal invasion, 
invasion <500 μm, and invasion ≥500 μm (P=0.298, P=0.175, and P=0.287, respectively) 
(Table 3). The MSI-H type of gastric cancer was significantly related to overall LVI and 
invasion ≥500 μm (P=0.027 and P=0.019, respectively). However, no statistically significant 
relationship was noted when the tumor invaded <500 μm (P=0.129) (Table 3). LVI was 
significantly associated with LN metastasis, regardless of MSI status. 47.4% (55 out of 116 
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Table 1. MSI status varies based on characteristics of enrolled patients
Characteristics Overall (n=1,156) MSS (n=1,071; 92.65%) MSI-H (n=85; 7.35%) P-value
Age (years) 57.8±11.6 56.7±11.5 63.4±10.7 <0.001
Sex <0.001
Male 759 (65.7) 720 (67.2) 39 (45.9)
Female 397 (34.3) 351 (32.8) 46 (54.1)
Location <0.001
Upper-third 95 (8.2) 92 (8.6) 3 (3.5)
Middle-third 352 (30.5) 339 (31.7) 13 (15.3)
Lower-third 708 (61.3) 639 (59.7) 69 (81.2)
Size (mm) 26.8±15.6 26.7±15.6 28.3±15.7 0.381
Histology <0.001
Differentiated 588 (51.6) 527 (50.0) 61 (71.8)
Undifferentiated 552 (48.4) 528 (50.0) 24 (28.2)
Lauren classification 0.002
Intestinal 570 (49.3) 516 (48.2) 54 (63.5)
Diffuse 370 (32.0) 357 (33.3) 13 (15.3)
Others 147 (12.7) 186 (17.4) 18 (21.2)
pT stage (%) 0.007
Mucosa 585 (50.6) 554 (51.7) 31 (36.5)
Submucosa 571 (49.4) 517 (48.3) 54 (63.5)
No. of resected LN 37.44±14.49 37.58±14.34 35.73±16.24 0.258
LN metastasis (%) 0.056
Yes 131 (11.3) 116 (10.8) 15 (17.6)
No 1,025 (88.7) 955 (89.2) 70 (82.4)
No. of metastatic LN 0.3±1.5 0.3±1.5 0.4±1.4 0.473
LVI 0.001
Yes 992 (85.8) 142 (13.3) 22 (25.9)
No 164 (14.2) 929 (86.7) 63 (74.1)
Values are expressed as mean±standard deviation or number (%).
MSI = microsatellite instability; MSS = microsatellite stable; MSI-H = microsatellite instability-high; LN = lymph node; 
LVI = lymphovascular invasion.
patients) and 9.1% (87 out of 955 patients) of MSS tumors, and 40.9% (9 out of 22 patients) 
and 9.5% (6 out of 63 patients) of MSI-H tumors were related to LN metastasis with and 
without LVI, respectively (P≤0.001 and P=0.002, respectively).
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Fig. 1. DFS Kaplan-Meier curves (A) in overall cohort, (B) in stage I. 
DFS = disease-free survival; HR = hazard ratio; CI = confidence interval; MSS = microsatellite stable; MSI-H = microsatellite instability-high.
Table 2. Cox regression analysis of DFS for each patient characteristic
Characteristics Univariate Multivariate
HR (95% CI) P-value HR (95% CI) P-value
Age 1.064 (1.042–1.087) <0.001 1.065 (1.042–1.088) <0.001
Sex <0.001 0.001
Male 1 1
Female 0.303 (0.165–0.558) 0.362 (0.196–0.668)
Location 0.865 -
Upper body 1 -
Middle body 1.268 (0.485–3.312) -
Lower body 1.430 (0.573–3.574) -
Size (mm) 1.012 (1.000–1.024) 0.047 1.008 (0.996–1.021) 0.196
Histology 0.035 0.397
Differentiated 1 1
Undifferentiated 0.620 (0.398–0.966) 1.311 (0.700–2.455)
Lauren classification 0.022 0.138
Intestinal 1 1
Diffuse 0.404 (0.224–0.729) 0.563 (0.251–1.263)
Others 1.068 (0.459–2.488) 1.189 (0.645–2.194)
pT stage 0.056 -
Mucosa 1 -
Submucosa 1.525 (0.990–2.349) -
No. of resected LN 0.986 (0.970–1.002) 0.084 - -
No. of metastatic LN 1.172 (1.101–1.248) <0.001 1.158 (1.091–1.229) <0.001
LN metastasis 0.105 -
No 1 -
YES 1.608 (0.906–2.852) -
LVI 0.024 0.348
No 1 1
Yes 1.799 (1.080–2.997) 1.292 (0.757–2.206)
MSI status 0.797 0.699
MSS 1 1
MSI-H 1.107 (0.511–2.398) 0.855 (0.387–1.890)
DFS = disease-free survival; HR = hazard ratio; CI = confidence interval; LN = lymph node; LVI = lymphovascular 
invasion; MSI = microsatellite instability; MSS = microsatellite stable; MSI-H = microsatellite instability-high.
We reviewed LN metastasis by MSI status in 307 patients who were candidates for endoscopic 
submucosal dissection (ESD) using both absolute and expanded criteria [28]. There were 
no LN metastases in either MSI-H or MSS types in 43 patients who met the absolute criteria 
for ESD (Fig. 3). Among 153 patients who satisfied one of the expanded criteria for ESD (size 
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Fig. 2. Kaplan-Meier curve for histologic type, pT stage, pN stage. 
LN = lymph node; DFS = disease-free survival; HR = hazard ratio; CI = confidence interval; MSS = microsatellite stable; MSI-H = microsatellite instability-high.
≤3 cm, differentiated histology, or mucosal invasion with ulcers), there was 1 case of LN 
metastasis in 10 MSI-H patients, and 1 in 143 MSS patients. In other patients with expanded 
criteria for ESD, there were no cases of LN metastasis in the MSI-H type of gastric cancer.
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Table 3. Comparison of MSI status, LN metastasis, and LVI depth
Variables pT1a (n=585) pT1b (n=571)
MSS (n=554) MSI-H (n=31) P-value MSS (n=517) MSI-H (n=54) P-value
LN metastasis 0.755 0.298
Yes 13 (2.35) 1 (3.23) 13/90 (16.0/20.6)* 0/14 (0.0/29.2)* 0.175†
No 541 (97.65) 30 (96.77) 68/346 (84.0/79.4)* 6/34 (100.0/70.8)* 0.287‡
LVI 0.755 0.027
Yes 13 (2.35) 1 (3.23) 11/118 (13.6/27.1)* 3/18 (50.0/37.5)* 0.129†
No 541 (97.65) 30 (96.77) 70/318 (86.4/72.9)* 3/30 (50.0/62.5)* 0.019‡
MSI = microsatellite instability; LN = lymph node; LVI = lymphovascular invasion; MSS = microsatellite stable; 
MSI-H = microsatellite instability-high.
*Sm1 (<500 μm)/Sm2, 3 (≥500 μm); number (%); †P-value of χ2 or Fisher's exact test between MSI status and 
LN metastasis/LVI on Sm1 stage gastric cancer; ‡P-value of χ2 or Fisher's exact test between MSI status and LN 
metastasis/LVI on Sm2, 3 stage gastric cancer.
ESD candidate (n=307)
Differentiated?
No
No
No
No
Yes
Yes
Yes
Yes
Mucosal cancer?
No ulceration?
Size  ≤20 mm
A (n=43)
LNM (+/−)
MSI-H (n=5) MSS (n=38)
0/5 0/38
B (n=41)
LNM (+/−)
MSI-H (n=7) MSS (n=34)
0/7 1/33
C (n=153)
LNM (+/−)
MSI-H (n=10) MSS (n=143)
1/9 1/142
D (n=36)
LNM (+/−)
MSI-H (n=3) MSS (n=33)
0/3 5/28
E (n=34)
LNM (+/−)
MSI-H (n=2) MSS (n=32)
0/2 1/31
Fig. 3. Patient distribution based on extended ESD indication. 
A. Tumor size ≤2 cm, histologically of differentiated type, pT1a, UL(−). 
B. Tumor size >2 cm, histologically of differentiated type, pT1a, UL(−). 
C. Tumor size ≤3 cm, histologically of differentiated type, pT1a, UL(+). 
D. Tumor size ≤2 cm, histologically of undifferentiated type, pT1a, UL(−). 
E. Tumor size ≤3 cm, histologically of differentiated type, pT1b (Sm1, ≤500 μm from the muscularis mucosae). 
ESD = endoscopic submucosal dissection; LNM = lymph node metastasis; MSS = microsatellite stable;  
MSI-H = microsatellite instability-high; UL = ulcerative lesion.
DISCUSSION
Contrary to our expectations, the present results showed that MSI status was not a prognostic 
indicator in patients with early gastric cancer. However, MSI-H gastric cancer was related 
to more aggressive tumors that exhibited deeper local invasion as well as LVI, with a trend 
towards an increase in LN metastasis.
Through efforts to understand the molecular biology of gastric cancer, clinically applicable 
biomarkers, such as ones for MSI, have been developed and validated for predicting 
prognosis and chemotherapeutic responses [7-9,22,23,29,30]. Previous studies regarding 
MSI in gastric cancer have focused on advanced-stage tumors. The MSI-H tumor status is 
predictive for immune checkpoint inhibitor responses in advanced or recurrent gastric cancer 
[31]. The MSI-H tumor status also serves as an indicator for the treatment of stage II/III 
tumors with only surgery since it is associated with a good prognosis, yet a poor response to 
chemotherapy [22,23]. Since early gastric cancer has a favorable prognosis, with 5-year DFS 
rates of 90%–95% [6,32], there would only be a small survival difference influenced by MSI 
status. The possibility of a type II error in the present results seemed to be low because there 
was no trend toward a different prognosis based on MSI status in the overall or subgroup 
analyses. Therefore, future biomarker studies regarding MSI status should focus on advanced 
gastric cancer, rather than early gastric cancer.
Prediction of LN metastasis is a clinically important challenge because limited resections, 
such as that with ESDs or partial gastrectomies with limited LN dissection, could be possible 
if there is certainty of no LN metastasis [28,33,34]. However, it is difficult to predict the 
presence of LN metastasis or LVI before surgery [4,20]. The less aggressive characteristics of 
MSI-H tumors in advanced gastric cancer suggest the likelihood that the MSI-H status could 
be inversely correlated to LN metastasis in early gastric cancer. We found a non-significant 
trend toward more LN metastases with MSI-H tumors. However, subgroup analyses of the 
depth of tumor invasion (mucosal and submucosal) showed no significant difference with 
respect to LN metastasis based on MSI status.
The present cohort included only patients with known MSI status and patients who underwent 
surgery, but patients who were treated by endoscopic resection were not considered. 
Consequently, there could be a selection bias. In addition, the mean tumor size in this cohort 
was larger than that in a previous study [4]. Presumably, these larger tumors signify a greater 
tumor invasion depth for the MSI-H tumors in this study. Since the depth of tumor invasion is 
strongly related to LN metastasis, one would expect the MSI-H tumors to be associated with 
more LN metastasis. However, there was no relationship between MSI-H tumors and higher 
LN metastasis when the tumor satisfied the ESD indications (Fig. 3). Therefore, it is difficult 
to conclude that the MSI-H phenotype in early gastric cancer is related to LN metastasis.
MSI-H tumors are related to increased immune signaling and a high mutational burden 
by neoantigens [31,35]. We found a significant positive relationship between LVI and the 
MSI-H status of gastric cancer in the overall pT1b group and the subgroup that has a depth of 
invasion ≥500 μm. This finding is not new as the same results have been reported previously 
[36-38]. This result can be explained by the possibility that immune cells are targeting an 
MSI-H tumor since there are more lymphatic vessels around the tumor, which increase the 
probability of tumor cell lymphatic invasion. However, the tumor cells can be detected and 
ultimately killed by the immune cells. The presence of LVI increases the risk of LN metastasis, 
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which is a contraindication for ESD treatment. Therefore, we should be cautious about 
expanding the indications for ESD in the future when there are MSI-H gastric cancers with 
submucosal invasion.
Although MSI is one of the well-defined and evaluated biomarkers in gastric cancer, 
molecular and clinical heterogeneity of MSI-H types have been reported: Intratumoral 
heterogeneity with both deficient and proficient MMR in a single patient has been reported 
[31,39] as well as stratified prognosis in MSI-H gastric cancer by expression of immune-
related markers [40-42], which implies that MSI-H types may be further stratified by 
additional molecular characteristics. Clinicians and researchers who study MSI-H gastric 
cancer need to recognize these important issues.
Although this study utilized the largest patient cohort for this subject, it is not without 
limitations due to the retrospective study design and the low number of deaths and tumor 
recurrence rates. The biomarkers selected for this population could also be subjected 
to selection bias. The results of this study need to be validated in other cohorts for 
confirmation.
In conclusion, MSI status is not a useful prognostic marker in patients with early gastric 
cancer. Frequent LVI of MSI-H gastric cancers, particularly invasion of the submucosa, could 
be a sign that careful patient selection for ESD or limited surgical intervention is necessary.
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